Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Holding MNTL?
Track your performance easily
MNTL Price & Analysis
MNTL ETF Chart & Stats
Day’s Range― - ―
52-Week Range$23.67 - $26.74
Previous Close$25.09
VolumeN/A
Average Volume (3M)429.00
AUM10.96M
NAV25.01
Expense Ratio0.75%
Holdings Count47
Beta1.14
Inception DateJan 22, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Shares OutstandingN/A
Standard DeviationN/A
10 Day Avg. VolumeN/A
30 Day Avg. Volume429
AlphaN/A
Tema Neuroscience and Mental Health ETF (MNTL) Fund Flow Chart
Tema Neuroscience and Mental Health ETF (MNTL) 1 year Net Flows: $11M
MNTL ETF News
MNTL ETF FAQ
What was MNTL’s price range in the past 12 months?
MNTL lowest ETF price was $23.67 and its highest was $26.74 in the past 12 months.
What is the AUM of MNTL?
As of May 07, 2024 The AUM of MNTL is 10.96M.
Is MNTL overvalued?
According to Wall Street analysts MNTL’s price is currently Undervalued.
Does MNTL pay dividends?
MNTL does not currently pay dividends.
How many shares outstanding does MNTL have?
Currently, no data Available
Which hedge fund is a major shareholder of MNTL?
Currently, no hedge funds are holding shares in MNTL
MNTL ETF Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
For ETFs, the calculations for the Smart Score, Analyst Consensus, Price Target, Blogger Sentiment, News Sentiment and Insider Transactions are based on the weighted average of the ETF's holdings and some additional factors. Hedge Fund Trend, Crowd Wisdom and Technicals are based on the actual ETF ticker.
Top 10 Holdings
Eli Lilly And Company
4.92%
Vertex Pharmaceuticals Inc.
4.66%
Regeneron Pharmaceuticals
4.62%
Neurocrine Biosciences
4.59%
Biogen Inc.
4.27%
Argenx
3.73%
Stryker Corp
3.66%
Dexcom
3.59%
Denali Therapeutics
3.38%
Crinetics Pharma
3.30%
Total40.73%
ETF Description
Tema Neuroscience and Mental Health ETF
MNTL is actively managed, concentrating on companies engaged in addressing disorders of the central nervous system and mental health worldwide. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive.